These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 32669858)

  • 1. Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection.
    Malandrakis P; Ntanasis-Stathopoulos I; Gavriatopoulou M; Terpos E
    Onco Targets Ther; 2020; 13():6405-6416. PubMed ID: 32669858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.
    Masood A; Iqbal Q; Ehsan H; Davis JA; Hansen DK; Hashmi H
    Ann Hematol; 2022 Dec; 101(12):2601-2610. PubMed ID: 36214853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
    Nooka AK; Costa LJ; Gasparetto CJ; Richardson PG; Siegel DS; Chari A; Lentzsch S; Jagannath S; Mikhael J
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e526-e531. PubMed ID: 35361554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy.
    Richard S; Jagannath S
    BioDrugs; 2022 Jan; 36(1):13-25. PubMed ID: 35113384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
    Qiu L; Xia Z; Fu C; Chen W; Chang C; Fang B; An G; Wei Y; Cai Z; Gao S; Weng J; Chen L; Jing H; Li F; Liu Z; Chen X; Liu J; Wang A; Yu Y; Xiang W; Lynch K; Yu Z; Fu W
    BMC Med; 2022 Apr; 20(1):108. PubMed ID: 35379237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
    Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
    J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
    Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
    J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selinexor in relapsed/refractory multiple myeloma.
    Richter J; Madduri D; Richard S; Chari A
    Ther Adv Hematol; 2020; 11():2040620720930629. PubMed ID: 32566115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selinexor: Targeting a novel pathway in multiple myeloma.
    Mo CC; Yee AJ; Midha S; Hartley-Brown MA; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
    EJHaem; 2023 Aug; 4(3):792-810. PubMed ID: 37601856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
    Chari A; Vogl DT; Gavriatopoulou M; Nooka AK; Yee AJ; Huff CA; Moreau P; Dingli D; Cole C; Lonial S; Dimopoulos M; Stewart AK; Richter J; Vij R; Tuchman S; Raab MS; Weisel KC; Delforge M; Cornell RF; Kaminetzky D; Hoffman JE; Costa LJ; Parker TL; Levy M; Schreder M; Meuleman N; Frenzel L; Mohty M; Choquet S; Schiller G; Comenzo RL; Engelhardt M; Illmer T; Vlummens P; Doyen C; Facon T; Karlin L; Perrot A; Podar K; Kauffman MG; Shacham S; Li L; Tang S; Picklesimer C; Saint-Martin JR; Crochiere M; Chang H; Parekh S; Landesman Y; Shah J; Richardson PG; Jagannath S
    N Engl J Med; 2019 Aug; 381(8):727-738. PubMed ID: 31433920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
    Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
    Gu X; Sun C; Xu J; Lin Z; Zhang L; Zheng Y
    Hematology; 2023 Dec; 28(1):2187972. PubMed ID: 36920065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
    Syed YY
    Target Oncol; 2023 Mar; 18(2):303-310. PubMed ID: 36622630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selinexor for the treatment of multiple myeloma.
    Podar K; Shah J; Chari A; Richardson PG; Jagannath S
    Expert Opin Pharmacother; 2020 Mar; 21(4):399-408. PubMed ID: 31957504
    [No Abstract]   [Full Text] [Related]  

  • 15. Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.
    Schiller GJ; Lipe BC; Bahlis NJ; Tuchman SA; Bensinger WI; Sutherland HJ; Lentzsch S; Baljevic M; White D; Kotb R; Chen CI; Rossi A; Biran N; LeBlanc R; Grosicki S; Martelli M; Gunsilius E; Špička I; Stevens DA; Facon T; Mesa MG; Zhang C; Van Domelen DR; Bentur OS; Gasparetto C
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e286-e296.e4. PubMed ID: 37393120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients.
    Delforge M; Raddoux J; Antonis C; Clement C; Kint N; Vanhellemont A; Bravetti J; Vandenberghe P
    Onco Targets Ther; 2022; 15():243-250. PubMed ID: 35310960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.
    Chen C; Siegel D; Gutierrez M; Jacoby M; Hofmeister CC; Gabrail N; Baz R; Mau-Sorensen M; Berdeja JG; Savona M; Savoie L; Trudel S; Areethamsirikul N; Unger TJ; Rashal T; Hanke T; Kauffman M; Shacham S; Reece D
    Blood; 2018 Feb; 131(8):855-863. PubMed ID: 29203585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study).
    Ehsan H; Robinson M; Voorhees PM; Cassetta K; Borden S; Atrash S; Bhutani M; Varga C; Pineda-Roman M; Friend R; Paul BA
    Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
    Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
    Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
    Peterson TJ; Orozco J; Buege M
    Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.